Literature DB >> 16879782

Hypertension and the pregnancy complicated by diabetes.

Gustavo F Leguizamón1, Natalia P Zeff, Alberto Fernández.   

Abstract

Diabetes is a frequent complication of pregnancy. Type 1 diabetes is associated with an increased incidence of preeclampsia and pregnancy-induced hypertension. When renal dysfunction is present, the incidence of these complications is remarkably increased. White's class, poor glycemic control during the first half of pregnancy, and early blood pressure elevation are also independent risk factors for developing preeclampsia. Whether gestational diabetes increases the background incidence of preeclampsia is still debated. Because therapeutic interventions such as low-dose aspirin and antioxidants have not been shown to be effective, preventive measures rely on tight blood glucose control, as well as adequate blood pressure treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16879782     DOI: 10.1007/s11892-006-0064-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  45 in total

1.  Treatment of hypertension in adults with diabetes.

Authors:  Carlos Arauz-Pacheco; Marian A Parrott; Philip Raskin
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

2.  Pregnancy induced hypertension in women with gestational carbohydrate intolerance: the diagest study.

Authors:  A Vambergue; M C Nuttens; P Goeusse; S Biausque; M Lepeut; P Fontaine
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2002-04-10       Impact factor: 2.435

3.  Urinary albumin excretion and 24-hour blood pressure as predictors of pre-eclampsia in Type I diabetes.

Authors:  P Ekbom; P Damm; K Nøgaard; P Clausen; U Feldt-Rasmussen; B Feldt-Rasmussen; L H Nielsen; L Mølsted-Pedersen; E R Mathiesen
Journal:  Diabetologia       Date:  2000-07       Impact factor: 10.122

4.  Preeclampsia in diabetic pregnancies.

Authors:  P R Garner; M E D'Alton; D K Dudley; P Huard; M Hardie
Journal:  Am J Obstet Gynecol       Date:  1990-08       Impact factor: 8.661

5.  Pregnancy outcome in type 1 diabetic women with microalbuminuria.

Authors:  P Ekbom; P Damm; B Feldt-Rasmussen; U Feldt-Rasmussen; J Mølvig; E R Mathiesen
Journal:  Diabetes Care       Date:  2001-10       Impact factor: 19.112

Review 6.  Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review.

Authors:  Aravinthan Coomarasamy; Honest Honest; Spyros Papaioannou; Harry Gee; Khalid Saeed Khan
Journal:  Obstet Gynecol       Date:  2003-06       Impact factor: 7.661

7.  Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial.

Authors:  L Poston; A L Briley; P T Seed; F J Kelly; A H Shennan
Journal:  Lancet       Date:  2006-04-08       Impact factor: 79.321

Review 8.  Screening for gestational diabetes: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Seth C Brody; Russell Harris; Kathleen Lohr
Journal:  Obstet Gynecol       Date:  2003-02       Impact factor: 7.661

9.  Diabetic nephropathy: pregnancy performance and fetomaternal outcome.

Authors:  E A Reece; D R Coustan; J P Hayslett; T Holford; J Coulehan; T Z O'Connor; J C Hobbins
Journal:  Am J Obstet Gynecol       Date:  1988-07       Impact factor: 8.661

10.  Hypertensive disorders of pregnancy in women with Type 1 and Type 2 diabetes.

Authors:  T Cundy; F Slee; G Gamble; L Neale
Journal:  Diabet Med       Date:  2002-06       Impact factor: 4.359

View more
  2 in total

1.  Understanding the association of biomedical, psychosocial and behavioral risks with adverse pregnancy outcomes among African-Americans in Washington, DC.

Authors:  Michele Kiely; Ayman A E El-Mohandes; Marie G Gantz; Dhuly Chowdhury; Jutta S Thornberry; M Nabil El-Khorazaty
Journal:  Matern Child Health J       Date:  2011-12

Review 2.  Managing type 1 diabetes mellitus in pregnancy--from planning to breastfeeding.

Authors:  Lene Ringholm; Elisabeth R Mathiesen; Louise Kelstrup; Peter Damm
Journal:  Nat Rev Endocrinol       Date:  2012-09-11       Impact factor: 43.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.